| P2093 | author name string | Gerolama Condorelli | |
| | Carlo Briguori | |
| | Cristina Quintavalle | |
| | Francesca De Micco | |
| P2860 | cites work | JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis | Q24554008 |
| | The Bcl-2 apoptotic switch in cancer development and therapy | Q24620437 |
| | From receptors to stress-activated MAP kinases | Q28137773 |
| | Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation | Q28199391 |
| | Prophylaxis strategies for contrast-induced nephropathy | Q28247353 |
| | Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development | Q28268881 |
| | Mitogen-activated protein kinase pathways | Q29618431 |
| | The stress-activated protein kinase subfamily of c-Jun kinases | Q29620001 |
| | N-acetylcysteine ameliorates renal microcirculation: studies in rats | Q30895638 |
| | Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy | Q33195952 |
| | N-acetylcysteine attenuates NSAID-induced rat renal failure by restoring intrarenal prostaglandin synthesis | Q33280737 |
| | A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity | Q33305487 |
| | Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy | Q33320267 |
| | Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine | Q33910096 |
| | N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up | Q33981981 |
| | Apoptosis signaling | Q34019359 |
| | Mitochondrial control of apoptosis: an overview | Q34034534 |
| | Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial | Q34176397 |
| | Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature | Q34495243 |
| | N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. | Q34542789 |
| | Contrast agent--associated nephrotoxicity | Q35151080 |
| | N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial | Q35584286 |
| | TRAIL and apoptosis induction by TNF-family death receptors. | Q35591708 |
| | N-acetylcysteine in the prevention of radiocontrast-induced nephropathy | Q35640707 |
| | Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature | Q35670852 |
| | N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. | Q35673022 |
| | Systematic review of the impact of N-acetylcysteine on contrast nephropathy | Q35746654 |
| | Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence | Q36375844 |
| | Contrast medium-induced nephropathy: the pathophysiology. | Q36448323 |
| | Pathophysiology of contrast-induced nephropathy | Q36584070 |
| | The apoptosome: signalling platform of cell death | Q36766418 |
| | N-acetylcysteine effect on serum creatinine and cystatin C levels in CKD patients | Q36947309 |
| | Contrast agents and renal cell apoptosis | Q39983835 |
| | Cyclic AMP reverses radiocontrast media-induced apoptosis in LLC-PK1 cells by activating A kinase/PI3 kinase. | Q40614498 |
| | Radiographic contrast media-induced tubular injury: evaluation of oxidant stress and plasma membrane integrity | Q40642492 |
| | Radiocontrast-induced DNA fragmentation of renal tubular cells in vitro: role of hypertonicity | Q41047081 |
| | Oxygen free radical involvement in urinary Tamm-Horsfall protein excretion after intrarenal injection of contrast medium | Q41225976 |
| | Safety and Cost Effectiveness of High-Osmolality as Compared with Low-Osmolality Contrast Material in Patients Undergoing Cardiac Angiography | Q41830247 |
| | N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration | Q43012450 |
| | Cystatin C and contrast-induced acute kidney injury. | Q43075382 |
| | Acetylcysteine for prevention of contrast nephropathy: meta-analysis | Q43799903 |
| | Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). | Q43865327 |
| | Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure | Q43975017 |
| | Acetylcysteine and contrast agent-associated nephrotoxicity | Q44054777 |
| | Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy | Q44200953 |
| | A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography | Q44213039 |
| | Attenuation of ischemia/reperfusion induced MAP kinases by N-acetyl cysteine, sodium nitroprusside and phosphoramidon | Q44252640 |
| | Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast | Q44320971 |
| | A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study | Q44487840 |
| | Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography | Q44683769 |
| | Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials | Q44719854 |
| | Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity | Q44769664 |
| | Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury | Q44885176 |
| | Platelet-activating factor increases endothelial [Ca2+]i and NO production in individually perfused intact microvessels | Q44907808 |
| | N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity | Q45019429 |
| | A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect | Q45075926 |
| | Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. | Q45209748 |
| | N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial | Q46105947 |
| | Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro | Q46450184 |
| | N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials | Q46861413 |
| | Hypoxia-induced apoptosis in cultured glomerular endothelial cells: involvement of mitochondrial pathways. | Q54741380 |
| P433 | issue | 3 | |
| P304 | page(s) | 165-173 | |
| P577 | publication date | 2010-12-08 | |
| P1433 | published in | Archives of Toxicology | Q635837 |
| P1476 | title | Nephrotoxicity of contrast media and protective effects of acetylcysteine | |
| P478 | volume | 85 | |